Biomarker for anti-tumor therapy KU Leuven
The invention relates to the field of biomarkers useful in monitoring anti-tumor therapy response, in particular response to immune checkpoint inhibitors. In particular, the biomarker identified herein is a plexin of the A-class, in particular plexin A4. More in particular expression of a plexin of the A-class in circulating T-cells, in particular circulating CTLs, is an early non-invasive biomarker for response to anti-tumor therapy. Methods of using this biomarker as well as kits relying on this biomarker are part of the invention.